News

Study Once More Underpins The Clinical Value Of FDA-Cleared Breast Cancer Recurrence Assay

Posted Date: December 22, 2010

Agendia, a world leader in molecular cancer diagnostics, announced recently that together with several groups of scientific collaborators it has identified a major role for TSPYL5 in the genesis of breast cancer.

Agendia, a world leader in molecular cancer diagnostics, announced recently that together with several groups of scientific collaborators it has identified a major role for TSPYL5, one of its MammaPrint breast cancer prognosis genes, in the genesis of breast cancer. The study entitled: “TSPYL5 suppresses p53 levels and function by physical interaction with USP7”, was published in Nature Cell Biology, one of the foremost scientific journals.

Click here to learn more.